Ejner Jensen
Directeur/Membre du Conseil chez Enduro Genetics ApS
Profil
Ejner Bech Jensen is currently the Director at Enduro Genetics ApS.
Previously, he worked as the Director of Molecular Biotechnology at Novo Nordisk A and Adenium Biotech ApS.
He also served as the Vice President of Molecular Biotechnology at Novozymes A from 2013 to 2014.
Before that, he was a Principal at Nordisk Gentofte A.
Postes actifs de Ejner Jensen
| Sociétés | Poste | Début |
|---|---|---|
Enduro Genetics ApS
 Enduro Genetics ApS Miscellaneous Commercial ServicesCommercial Services Enduro Genetics ApS is a Danish biotechnology research company that specializes in developing bio products. The company is based in Copenhagen, Denmark. Enduro Genetics was founded by Peter Rugbjerg and Christian Munck. The CEO is Christian Munch. | Directeur/Membre du Conseil | - |
Anciens postes connus de Ejner Jensen
| Sociétés | Poste | Fin |
|---|---|---|
Novozymes A/S
 Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | Directeur Technique/Scientifique/R&D | - |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
| Nordisk Gentofte A/S | Corporate Officer/Principal | - |
Adenium Biotech ApS
 Adenium Biotech ApS Pharmaceuticals: MajorHealth Technology Adenium Biotech ApS develops and commercializes novel antibiotics for the treatment of multi drug resistant bacterial infections. It focuses on treatment of nosocomial infections, in particular complicated urinary tract infections and hospital or ventilator acquired pneumonia caused by multi drug resistant Gram-negative bacteria. The company offers Arenicin, an anti-microbial peptide against gram-negative pathogens for pneumonia, urinary tract infection, and acinetobacter baumanii. Adenium Biotech was founded by Peter Nordkild on August 24, 2011 and is headquartered in Copenhagen, Denmark. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| Entreprise privées | 4 |
|---|---|
Adenium Biotech ApS
Adenium Biotech ApS Pharmaceuticals: MajorHealth Technology Adenium Biotech ApS develops and commercializes novel antibiotics for the treatment of multi drug resistant bacterial infections. It focuses on treatment of nosocomial infections, in particular complicated urinary tract infections and hospital or ventilator acquired pneumonia caused by multi drug resistant Gram-negative bacteria. The company offers Arenicin, an anti-microbial peptide against gram-negative pathogens for pneumonia, urinary tract infection, and acinetobacter baumanii. Adenium Biotech was founded by Peter Nordkild on August 24, 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
| Nordisk Gentofte A/S | |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | Process Industries |
Enduro Genetics ApS
Enduro Genetics ApS Miscellaneous Commercial ServicesCommercial Services Enduro Genetics ApS is a Danish biotechnology research company that specializes in developing bio products. The company is based in Copenhagen, Denmark. Enduro Genetics was founded by Peter Rugbjerg and Christian Munck. The CEO is Christian Munch. | Commercial Services |